Analyst Price Target is $19.00
▲ +102.77% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Coherus BioSciences in the last 3 months. The average price target is $19.00, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 102.77% upside from the last price of $9.37.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Coherus BioSciences. This Buy consensus rating has held steady for over two years.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.